We previously found, using a mouse model, that activation of proinflammatory cytokines after acute myocardial infarction (AMI) augments neointimal hyperplasia of a remote artery. The present study assessed the progression of luminal narrowing of non-culprit coronary arteries (NCCA) in patients following AMI. Methods: The study group comprised 21 AMI patients successfully treated with bare-metal stents and 16 stable angina (SA) patients treated with sirolimus-eluting stents. Clinical backgrounds were similar for both groups. Quantitative coronary angiography was performed before and after stent implantation and at 6-months of follow-up. 
have significantly decreased acute procedural complications, but have been unable to prevent chronic instent restenosis [5] [6] [7] [8] . Sirolimus-eluting stent (SES) implantation significantly decreased the chronic in-stent restenosis rate to 5-7% through its anti-inflammatory effects, inhibiting several regulators of cell-cycle progression, and the migration of vascular smooth-muscle cells 9, 10) . Although SES implantation has the potential risk of late thrombosis after the stopping of antiplatelet therapy 11, 12) 
Introduction
Percutaneous coronary intervention (PCI), first performed in 1968 1) , has dramatically improved the outcome of treatment for coronary artery disease (CAD). Even conventional plain balloon angioplasty has significantly improved ischemia-related symptoms, but, periprocedural complications such as acute artery occlusion and chronic restenosis occur in approximately 5 and 40% of cases, respectively [2] [3] [4] . Bare-metal stent (BMS) implantation and ticlopidine administration inflammatory response and vulnerable plaques than SA. Furthermore, subsequent coronary events including recurrent AMI and in-stent restenosis after PCI are more frequent in patients with AMI than with SA.
The plasma concentrations of various proinflammatory cytokines and growth factors, including tumor necrotic factor-(TNF-), interleukin-1 (IL-1 ), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) are significantly elevated for approximately 2 weeks after onset 20, 21) in the setting of AMI, but only slightly elevated in that of SA. We previously found, using a mouse model, that the activation of proinflammatory cytokines after AMI augments the neointimal hyperplasia of a remote artery 22) . However, the augmentation of neointimal hyperplasia of non-culprit coronary arteries in patients after AMI has not been investigated in detail.
The present study evaluates the progression of luminal narrowing among non-culprit coronary arteries in patients after AMI.
Subjects and Methods

Subjects
We examined consecutive patients with AMI and SA who underwent initial coronary angiography, were successfully treated by stent implantation for significant coronary artery stenosis ( 75% luminal narrowing), and were assessed by 6-month follow-up angiography between June 2004 and June 2005. Acute myocardial infarction was defined as typical chest pain at rest lasting 30 minutes accompanied by both STsegment and/or T-wave elevation on electrocardiography (ECG), elevation of creatine kinase to twice the upper normal limit, and positive response of the cardiac troponin T rapid assay. Stable angina pectoris was defined as effort-related chest pain without any clinical changes in the preceding 2 months and negative cardiac troponin T. We performed PCI when indicated from the results of an exercise electrocardiography test and myocardial scintigraphy. We excluded the following patients to minimize the inflammatory response induced by stimulation other than AMI, SA, and the first coronary stenting procedure: (1) patients with in-hospital death after the primary procedure; (2) patients with AMI within 2 weeks of the primary procedure (to exclude potential subacute stent thrombosis of the treated arterial segment); (3) patients treated with a debulking device such as a rotablator or directional coronary atherectomy and (4) patients that underwent a second elective PCI, coronary artery bypass grafting, or other surgery within the 6-month follow-up period. We finally enrolled 21 AMI and 16 SA patients in this study.
All of the enrolled patients were systematically administered both aspirin (81-100 mg/day) and ticlopidine (200 mg/day). In the event of adverse reactions to ticlopidine, cilostazol (150-200 mg/day) was prescribed instead. None of the patients was receiving hormone replacement therapy. There was no cardiac event in any of the patients throughout the study. This protocol was approved by our institutional ethics committee (#2002-009), and was performed in accordance with the Helsinki Declaration of 1975.
Coronary Risk Factors
Peripheral venous blood samples were withdrawn from patients after at least a 12-h fast, in the morning, upon admission, and at 6-months follow-up to evaluate the following coronary risk factors: age, gender, body mass index (BMI), smoking habit, blood pressure (BP), glycated hemoglobin A1c (HbA1c), triglyceride (TG), total cholesterol (T-Cho), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Levels of HbA1c were measured by high-performance liquid chromatography and those of TG, T-Cho, and HDL-C, by standard enzymatic methods. Levels of LDL-C were calculated using the Friedwald formula (T-cho HDL-C TG/5), because TG concentrations were 400 mg/dL in all patients. Hypertension was defined as repeated measurements 140 mmHg systolic BP and/or 90 mmHg diastolic BP and/or on permanent antihypertensive drug therapy. Dyslipidemia was defined as TG 150 mg/dL and/or HDL-C 40 mg/dL and/or LDL-C 140 mg/dL 23) . Diabetes mellitus (DM) was defined as a fasting blood glucose concentration of 126 mg/dL and/or HbA1c 6.5% and/or receiving antihyperglycemic drug therapy.
In all patients, coronary risk factors were treated according to Japanease studies and guidelines [24] [25] [26] . No restrictions were placed on the administration of medication.
Inflammatory Markers
Serial changes in inflammatory markers were determined in peripheral venous blood samples that were withdrawn from patients with AMI in the morning after at least a 12-h-fast. The white blood cell (WBC) count and the C-reactive protein (CRP) concentration were measured everyday until they reached peak values after stent implantation, using an automated hematology analyzer and an automated latex immunoturbidimetric assay, respectively. The WBC counts and CRP concentrations in the SA patients determined at the first day after stent implantation were defined as the peak values respectively, when within normal ranges.
Cardiac Function
B-type natriuretic peptide (BNP) was measured and echocardiography was performed at 6-months of follow-up, to evaluate cardiac function. Venous plasma BNP concentrations were measured using a radioimmunoassay (Shionoria BNP kit, Shionogi Co Ltd, Osaka, Japan). Echocardiograms were obtained using an ACUSON Sequoia Ultrasound Imaging System (Siemens, Erlangen, Germany). Ejection fraction (EF) was calculated using the modified Sympson's rule 27) .
Quantitative Coronary Angiography
We used the Judkins percutaneous femoral artery approach technique for coronary angiography. Multiple views of the right and left coronary arteries were routinely recorded on a full digital imaging system equipped with a flat-panel detector (AXIOM Artis FC/BC, Siemens, Erlangen, Germany; Allura Xper FD10, Philips, Eindhoven, the Netherlands). Angiographic images were obtained after the administration of 200 g of intracoronary nitroglycerine.
Quantitative coronary angiographic (QCA) analysis was performed by a trained observer blind to the clinical background of subjects, using QCA-CMS software (MEDIS Medical Imaging Systems, Leiden, The Netherlands), in which coronary lumen diameters were measured using an automated edge-contour detection system. We evaluated both culprit and non-culprit coronary arteries. A culprit coronary artery was determined from ECG and echocardiographic findings, and the presence of stenosis and residual thrombosis in the artery. Non-culprit coronary arteries were defined as two coronary arteries (excluding the stented culprit coronary artery), and were limited to the proximal and mid coronary segments (AHA #1, 2, 3, 6, 7, 11, 12, 13). Angiographic images before (pre-procedure) and immediately after (post-procedure) stent implantation, as well as at the 6-month follow-up (chronic phase) were selected in the same view to clearly visualize narrowed lesions.
The lengths of the lesions were calibrated based on the image of the contrast-filled guiding catheter. The reference diameter (mm), minimal lumen diameter (MLD) (mm), and diametric stenosis (%) were measured in each segment of the culprit and non-culprit coronary arteries. The diametric stenosis was defined as [(reference diameter MLD)/reference diameter] 100. The diameter gained by treatment (acute gain post-procedure MLD pre-procedure MLD) (mm) and the luminal loss in the chronic phase (late loss post-procedure MLD chronic phase MLD) (mm) were determined in the culprit coronary artery. We also determined the absolute change in MLD (mm) and diametric stenosis (%) between pre-procedure and chronic phase in the non-culprit coronary arteries. A coronary diametric stenosis of 50% was considered clinically significant.
Statistics
Statistical analysis was performed using StatView 4.5 MDSU statistical software (Abacus Concept, Inc., Berkeley, CA, USA). Data are presented as the mean standard deviation (SD). Continuous quantitative data were compared using a matched Student's t test and discontinuous quantitative data were compared using the 2 test. Correlations between continuous variables were determined using a linear regression analysis. Statistical significance was established when p 0.05.
Results
Patient Characteristics
The baseline clinical background, excluding gender and hypertension, did not significantly differ between the two groups ( Table 1) . The clinical background at 6-months of follow-up, excluding systolic BP and EF on echocardiograms, was also similar between the two groups, and coronary risk factors were controlled well ( Table 2) . Systolic BP was significantly lower in patients with AMI than with SA, probably because the EF was significantly lower, and treatment with a angiotensin-converting enzyme inhibitor was somewhat more frequent in those with AMI. Table 3 shows that the patients with AMI were implanted with a total of 22 BMS (BX velocity stent, 6; Duraflex stent, 6; Penta stent, 4; Driver stent, 3; Zeta stent, 2; s670 stent, 1), and those with SA were implanted with a total of 21 SES. The procedural characteristics, excluding stent diameter, were similar between the two groups. Peak WBC counts and peak CRP concentrations after PCI were significantly higher in the AMI than SA group (p 0.0001, p 0.0001, respectively). Peak WBC counts and peak CRP concentrations in the SA group were within the normal ranges. Table 4 shows the angiographic findings of culprit coronary arteries. The number of coronary artery stenoses and the location of stented coronary arteries were similar between the two groups. Most patients had single vessel stenosis because those with multivessel stenosis underwent elective PCI or coronary artery bypass grafting, and were excluded from the present study. The reference diameter was significantly larger in the AMI than SA group (3.02 0.59 vs. 2.20 0.31, p 0.0001), and pre-procedure MLD was significantly smaller in the AMI group (0.35 0.48 vs. 0.92 0.66, p 0.01). Post-procedure MLD was sufficiently large in both the groups, and did not significantly differ Table 5 shows the angiographic findings of 126 non-culprit coronary segments (AMI, 73 segments; SA, 53 segments). Pre-procedure MLD (mm) was significantly larger in the AMI than SA group (2.61 0.78 vs. 2.02 0.56, p 0.0001). At the 6-month follow-up, the decrease in MLD was more frequent in the AMI (42 segments, 57.5%) than SA (25 segments, 47.1%) group. The frequency of an MLD decrease per patient was greater in the AMI (54.2 31.7%) than SA (44.0 36.1%) group, although this difference was not significant. The MLD (mm) decreased significantly from 2.61 0.79 to 2.44 0.71 in patients with AMI (p 0.01), but changed only slightly from 2.02 0.56 to 2.02 0.50 in SA patients (p 0.84). The absolute change (mm) in MLD between pre-procedure and the chronic phase was significantly greater in the AMI than the SA group (0.17 0.53 vs. 0.0070 0.26, p 0.05).
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Neither peak WBC count, peak CRP concentration, TG, T-Cho, HDL-C, nor LDL-C correlated with the MLD decrease in each group.
Discussion
Culprit Lesions
The reference diameter of the culprit lesion was significantly larger in the AMI than SA group, which is consistent with the findings of Hong et al. 28) . Late loss (mm) was 0.94 0.67 after BMS implantation in the AMI group, and 0.24 0.35 after SES implantation in the SA group. These findings were compatible with those of others [5] [6] [7] [8] [9] [10] and support the accuracy of the QCA used in the present study.
Non-Culprit Lesions
The present results support the notion that the activation of proinflammatory cytokines after AMI augments the neointimal hyperplasia of remote arteries. In patients with AMI whose WBC count and CRP concentration were elevated, the MLD (mm) of nonculprit coronary arteries significantly decreased from 2.61 0.79 to 2.44 0.71 within 6 months after stent implantation (p 0.01), whereas the change was minimal in SA patients without such elevations (from 2.02 0.56 to 2.02 0.50; p 0.84).
We used the WBC count and CRP concentration as inflammatory markers because of the absence of surplus blood samples, although we previously reported that activated TNF-and IL-6 augment neointimal hyperplasia 22) . Hasegawa et al. reported that the WBC count is closely related to other conventional coronary risk factors and is an important indicator of chronic inflammation 29) . The CRP concentration becomes elevated after balloon angioplasty 30) and stent implantation 31) , and predicts in-stent restenosis within 12-months follow-up 32) . Therefore, the WBC count and the CRP concentration are considered appropriate for evaluating inflammation after AMI. Hong et al. compared coronary plaque rupture between AMI and SA using three-vessel intravascular ultrasound 28) , and reported that both non-culprit and culprit coronary plaque rupture are more frequent in patients with AMI than with SA. Plaque rupture in AMI patients was associated with a high CRP concentration, whereas that in SA patients was associated with diabetes. These findings are consistent with those of the present study, suggesting that inflammation after AMI increases the vulnerability of non-culprit arteries to atheromatous plaques. Despite the reduction in in-stent restenosis rates by SES, this does not demonstrate an improvement of long-term prognosis 10, 12) . One cause of this discrepancy might be the progression of atherosclerosis in non-culprit arteries. For the reasons stated above, careful management of non-culprit coronary arteries is critical to further improve the long-term prognosis of patients with AMI.
In contrast, systemic effects of the elution of sirolimus remain controversial. An implanted SES was reportedly associated with exercise-induced paradoxical coronary vasoconstriction of the adjacent vessel segments 33) . Furthermore, the implantation of SES suppressed, whereas the implantation of BMS induced, the mobilization and differentiation into both smooth muscle-like and endothelium-like cells of bone marrow cells, possibly leading to restenosis 34) . However, the reported peak sirolimus concentration after SES implantation is approximately 0.86-2.00 ng/mL, far lower than the effective concentration when sirolimus is orally administered as an immunosuppressive agent 35) . In the present study, SA patients received SES, and AMI patients received BMS. Therefore, systemic effects after SES implantation might have inhibited atherosclerosis in non-culprit coronary arteries.
Study Limitations
The present study has four potential limitations. First, we retrospectively analyzed a relatively small sample of patients. Second, we routinely use 4F coronary catheters for coronary angiography to minimize the invasive effect on patients. The use of small catheters as a calibration standard may induce measurement bias for QCA. Third, QCA cannot clarify the cause of luminal narrowing in non-culprit coronary arteries. Ehara et al. reported that plaque morphology and pathology are closely related to progression characteristics 18) . Fourth, we used the peak WBC count and peak CRP concentration as inflammatory markers, although they are non-specific in this context. Moreover, we could not calculate the area under the curve (AUC) for these markers. Thus, we could indicate that the inflammation is related to the progression of non-culprit coronary artery atherosclerosis, but could not clarify whether the degree of inflammation is related to the progression and/or severity of the atherosclerosis.
Finally, our results should be confirmed by further prospective studies with large cohorts using specific inflammatory markers and other imaging methods, such as coronary computed tomography, cardiac magnetic resonance imaging, intravascular ultrasound (IVUS), and optical coherence tomography (OCT).
Conclusion
Within 6 months of stent implantation, luminal narrowing of non-culprit coronary segments had clearly progressed in patients with AMI, but progressed minimally in patients with SA.
